A more comprehensive phospho-proteomic analysis was carried out on the early HR-negative/HER2-positive BC and TNBC population of the I-SPY2 trial, with high pAKT, pSGK, pmTOR, and pTSC2 levels prior to neoadjuvant treatment with MK-2206 and standard therapy positively correlating with pCR rates (Wolf et al., 2020). This evidence concerns the gene ERBB2 and breast cancer.